Home > News > Case Study > 2023

How WuXi ATU Drives CGT Development amidst Industry Challenges
2023年7月6日→
WuXi ATU Wins Tech Disruptor at the Advanced Therapies Awards 2023!
2023年1月23日→
WuXi ATU and Suzhou GenAssist Therapeutics Announce Strategic Partnership of Cooperation to develop novel AAV therapies
2022年9月27日→

How WuXi ATU Drives CGT Development amidst Industry Challenges

Previous news

2023年8月23日 LentiVV Stable | New Generation LVV Production Technology
2023年6月6日 WuXi ATU and T-MAXIMUM Announce Strategic Partnership of Cooperation for MT-027 UCAR-T
2023年5月17日 Interius BioTherapeutics Announces Successful Manufacturing Partnership with WuXi Advanced Therapies
2023年3月8日 Clinical Phase I/II IND Approval! The First Cell Therapy Project in Korea Supported by WuXi Advanced Therapies Receives MFDS Approval

共 1页4条记录

TOP

无锡生基医药科技有限公司 WuXi ATU Co., Ltd.

Tel:+86（510）8858 3666

Email: info_atu@wuxiapptec.com

Address: Floor D7-5, Huishan Life Science Industrial Park, No. 1719 Huishan Avenue,
Huishan Economic Development Zone, Wuxi, Jiangsu Province

WuXi Advanced Therapies

© 2020 WuXi AppTec. Su ICP Bei No. 19024771, Su Gong Net AnBei No. 31019002000568

Terms of use Privacy statement Friendly Link